BRPI0910232A2 - formas de sais inibidores do mtor - Google Patents

formas de sais inibidores do mtor

Info

Publication number
BRPI0910232A2
BRPI0910232A2 BRPI0910232A BRPI0910232A BRPI0910232A2 BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2 BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2
Authority
BR
Brazil
Prior art keywords
salt forms
inhibitor salt
inhibitor
forms
salt
Prior art date
Application number
BRPI0910232A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Gary C Visor
Josef A Rechka
Kristen Michelle Mulvihill
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0910232A2 publication Critical patent/BRPI0910232A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910232A 2008-03-19 2009-03-18 formas de sais inibidores do mtor BRPI0910232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7006208P 2008-03-19 2008-03-19
PCT/US2009/037505 WO2009117482A1 (en) 2008-03-19 2009-03-18 Mtor inhibitor salt forms

Publications (1)

Publication Number Publication Date
BRPI0910232A2 true BRPI0910232A2 (pt) 2015-09-29

Family

ID=40597405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910232A BRPI0910232A2 (pt) 2008-03-19 2009-03-18 formas de sais inibidores do mtor

Country Status (12)

Country Link
US (1) US8557814B2 (pt)
EP (1) EP2276763A1 (pt)
JP (1) JP2011515410A (pt)
KR (1) KR20110017845A (pt)
CN (1) CN101977912A (pt)
AU (1) AU2009225614A1 (pt)
BR (1) BRPI0910232A2 (pt)
CA (1) CA2716924A1 (pt)
EA (1) EA018144B1 (pt)
MX (1) MX2010010300A (pt)
WO (1) WO2009117482A1 (pt)
ZA (1) ZA201006641B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316605B2 (en) * 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
JP2011515410A (ja) 2008-03-19 2011-05-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 塩の形のｍＴＯＲ阻害剤
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
PE20140236A1 (es) 2011-02-23 2014-03-14 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
JP6946001B2 (ja) * 2014-03-06 2021-10-06 ピーティーシー セラピューティクス， インコーポレイテッド 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
MX2021007536A (es) * 2018-12-21 2021-09-23 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0783505T3 (da) 1994-09-29 2001-07-02 Novartis Ag Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
ATE242245T1 (de) 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1425284A2 (en) 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
WO2005054268A1 (en) 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007079164A2 (en) 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
TW200738725A (en) 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
WO2007106503A2 (en) * 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
JP2011500657A (ja) 2007-10-15 2011-01-06 アストラゼネカ アクチボラグ 組合せ０５９
JP2011515410A (ja) 2008-03-19 2011-05-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 塩の形のｍＴＯＲ阻害剤
CN102471292A (zh) 2009-07-09 2012-05-23 Osi药物有限责任公司 取代的3-氨基-5-氧代-4,5-二氢-[1,2,4]三氮烯的方法
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY

Also Published As

Publication number Publication date
MX2010010300A (es) 2010-10-26
US8557814B2 (en) 2013-10-15
ZA201006641B (en) 2011-05-25
EA201071099A1 (ru) 2011-02-28
AU2009225614A1 (en) 2009-09-24
JP2011515410A (ja) 2011-05-19
CA2716924A1 (en) 2009-09-24
CN101977912A (zh) 2011-02-16
WO2009117482A8 (en) 2010-04-08
EP2276763A1 (en) 2011-01-26
WO2009117482A1 (en) 2009-09-24
US20110015197A1 (en) 2011-01-20
EA018144B1 (ru) 2013-05-30
KR20110017845A (ko) 2011-02-22

Similar Documents

Publication Publication Date Title
BRPI0910232A2 (pt) formas de sais inibidores do mtor
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
FIC20200046I1 (fi) Alpelisibi tai sen suola
BRPI0922466A2 (pt) sais
BRPI0917808A2 (pt) inibidores de cmet
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0906764A2 (pt) Processos
EP2266026A4 (en) EFFICIENT DETERMINIST MULTIPLE PROCESSING
BRPI0911175A2 (pt) conjuntos de válvula
BRPI0821868A2 (pt) Grânulo
BRPI0924163A2 (pt) kit de limpeza de arma de fogo
BRPI0908115A2 (pt) torneira
BRPI0919591A2 (pt) válvula magnética
BRPI0918564A2 (pt) inibidores
BRPI0914781A2 (pt) Microbiocidas
BRPI0908513A2 (pt) válvula
BRPI0911625A2 (pt) Métodos
EP2317192A4 (en) MAGNETIC VALVE
FR2914943B1 (fr) Aube de soufflante
BRPI0821901A2 (pt) Válvula homogeneizadora
BRPI0909106A2 (pt) Método herbicida
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
DE602007002163D1 (de) Weichspülmittel
IT1394067B1 (it) Valvola

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.